Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495153 · ClinicalTrials.gov registry record · Phase 2
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Candel Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 14
- Study locations
NCT04495153 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Candel Therapeutics. The registered enrollment target is 90 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 14 study locations across 12 states.
The verdict
NCT04495153, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Candel Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.
Conditions Studied
Interventions
- BIOLOGICAL Aglatimagene besadenovec
Study Locations (14)
Connecticut
- UConn Health - Farmington
- Yale University, Yale Cancer Center - New Haven
Virginia
- Hunter Holmes McGuire VA Medical Center - Richmond
- Virginia Commonwealth University - Richmond
Arizona
- Mayo Clinic Hospital - Phoenix
Illinois
- University of Chicago - Chicago
Maryland
- University of Maryland, Baltimore - Baltimore
Minnesota
- Mayo Clinic - Rochester
New York
- NYU Langone Health - New York
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495153
The ClinicalTrials.gov registry entry for NCT04495153 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Candel Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Aglatimagene besadenovec is the first listed.
NCT04495153 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Connecticut, Virginia, Arizona.
Frequently Asked Questions
What is clinical trial NCT04495153 about?
NCT04495153 is a clinical study titled "CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC". The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy appr...
What is the current status of trial NCT04495153?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2020-10-13. Estimated completion is 2026-12.
What conditions does trial NCT04495153 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04495153?
The interventions under investigation include: Aglatimagene besadenovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT04495153?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04495153 being conducted?
This trial has 14 study locations across Arizona, Connecticut, Illinois, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.